BioSpace News Archive

Osteal Therapeutics, Inc. announced the expansion of its leadership team with the appointments of Kathy Burke as Vice President of Market Access, Clay Cohorn as Vice President of Clinical Affairs, Trey Putnam, PhD, RAC as Vice President of Regulatory Affairs and Quality Assurance, and Todd Saunders as Vice President of Marketing.

TransCode Therapeutics, Inc., the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced that it has received written authorization from the U.S. Food and Drug Administration that it may proceed with its First-in-Human Phase 0 clinical trial.

Neogen Corporation announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office.

Complete Genomics Inc announced that it is presenting at Biotech Showcase™ 2023, taking place in San Francisco at the same time as the JP Morgan healthcare conference.

MediWound Ltd. announced that the U.S. Food and Drug Administration has approved NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.

Retractable Technologies, Inc. announces that it has agreed to repurchase three million shares of its common stock in a private transaction with BML Investment Partners, L.P. Braden M. Leonard, on behalf of the selling shareholder, approached the Company with an offer to sell a block of shares prior to year-end.

SomaLogic, Inc., a leader in proteomics technology, announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Sesen Bio, Inc. and Carisma Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced an amendment to their previously announced merger agreement dated September 20, 2022.

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Company’s management will host conference calls to introduce its new corporate strategy.